Published in Circulation on February 04, 1997
Arterial thrombosis--insidious, unpredictable and deadly. Nat Med (2011) 1.96
Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective. Crit Care (2006) 1.58
Intercellular calcium communication regulates platelet aggregation and thrombus growth. J Cell Biol (2003) 1.42
Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin alpha2beta1, and von Willebrand factor. J Biol Chem (2007) 1.38
T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37
Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. BMC Nucl Med (2006) 1.27
The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell Metab (2012) 1.24
Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. Anesth Analg (2011) 1.17
The biology behind the atherothrombotic effects of cigarette smoke. Nat Rev Cardiol (2013) 1.10
Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med (2007) 1.07
Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol (2012) 1.01
Aegyptin displays high-affinity for the von Willebrand factor binding site (RGQOGVMGF) in collagen and inhibits carotid thrombus formation in vivo. FEBS J (2009) 1.01
Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A (2012) 0.99
Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Control Release (2008) 0.95
Platelets in inflammation and atherogenesis. Front Immunol (2015) 0.94
Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1α and vascular endothelial growth factor signaling. Circulation (2014) 0.91
Dyslipidaemia in rheumatological autoimmune diseases. Open Cardiovasc Med J (2011) 0.90
Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur Heart J Acute Cardiovasc Care (2012) 0.88
Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost (2009) 0.86
Caspase-1-mediated pathway promotes generation of thromboinflammatory microparticles. J Clin Invest (2015) 0.86
Fibrin, γ'-fibrinogen, and transclot pressure gradient control hemostatic clot growth during human blood flow over a collagen/tissue factor wound. Arterioscler Thromb Vasc Biol (2015) 0.83
Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor downregulation via suppression of nuclear factor-kappa B in endothelial cells. Asian J Androl (2009) 0.82
Detection of tissue factor antigen and coagulation activity in coronary artery thrombi isolated from patients with ST-segment elevation acute myocardial infarction. PLoS One (2013) 0.81
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well? Curr Cardiol Rev (2010) 0.80
4-Hydroxy-2-nonenal enhances tissue factor activity in human monocytic cells via p38 mitogen-activated protein kinase activation-dependent phosphatidylserine exposure. Arterioscler Thromb Vasc Biol (2013) 0.79
Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J Physiol (2016) 0.79
Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci U S A (2001) 0.78
The Eph tyrosine kinase receptors EphB2 and EphA2 are novel proteolytic substrates of tissue factor/coagulation factor VIIa. J Biol Chem (2014) 0.78
NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes. Br J Pharmacol (2001) 0.78
Tissue factor pathway inhibitor as a multifunctional mediator of vascular structure. Front Biosci (Elite Ed) (2012) 0.77
Common pathways of hypercholesterolemia and hypertension leading to atherothrombosis: the need for a global approach in the management of cardiovascular risk factors. Vasc Health Risk Manag (2007) 0.75
High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. Nutrients (2017) 0.75
Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. PLoS One (2017) 0.75
Impact of commonly prescribed exercise interventions on platelet activation in physically inactive and overweight men. Physiol Rep (2016) 0.75
Comparison of coronary arterial lumen dimensions on angiography and plaque characteristics on optical coherence tomography images and their changes induced by statin. BMC Med Imaging (2016) 0.75
"Soluble Tissue Factor" in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation. Semin Thromb Hemost (2015) 0.75
Study of Erythrocyte Indices, Erythrocyte Morphometric Indicators, and Oxygen-Binding Properties of Hemoglobin Hematoporphyrin Patients with Cardiovascular Diseases. Adv Hematol (2017) 0.75
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Coronary plaque disruption. Circulation (1995) 8.04
Idiopathic dilated cardiomyopathy. N Engl J Med (1994) 7.74
The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med (1992) 6.41
Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood (1979) 6.01
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation (1987) 5.73
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation (1999) 5.62
Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol (1987) 5.33
A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol (1995) 4.43
Coarctation of the aorta. Long-term follow-up and prediction of outcome after surgical correction. Circulation (1989) 4.32
Blood coagulation. Annu Rev Biochem (1980) 4.27
Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med (1993) 3.90
The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med (1992) 3.53
The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature (1996) 3.40
Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Writing Group. Circulation (1996) 3.34
Restrictive cardiomyopathy. N Engl J Med (1997) 3.29
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med (1992) 3.16
Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation (1984) 3.15
Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol (1988) 3.10
Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol (1997) 3.06
Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A (1999) 2.98
Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation (2000) 2.94
Developmental regulation of cryptdin, a corticostatin/defensin precursor mRNA in mouse small intestinal crypt epithelium. J Cell Biol (1989) 2.81
Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation (1994) 2.77
HIV/HTLV gene nomenclature. Nature (1988) 2.72
Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation (2001) 2.71
Specific Tissue Reaction to Phospholipids: A Suggested Explanation for the Similarity of the Lesions of Silicosis and Pulmonary Tubercolosis. Can Med Assoc J (1937) 2.67
Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest (1990) 2.55
Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation (1991) 2.52
Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation (1996) 2.46
The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol (1981) 2.44
Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation (2001) 2.41
Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res (2001) 2.35
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol (1992) 2.30
Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol (1990) 2.30
Noninvasive in vivo human coronary artery lumen and wall imaging using black-blood magnetic resonance imaging. Circulation (2000) 2.29
Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation (1995) 2.29
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor. J Biol Chem (1977) 2.21
Neointimal proliferation in canine coronary arteries. A model of restenosis permitting local and continuous drug delivery. Lab Invest (1994) 2.15
Brief report: recognition of acute myocarditis masquerading as acute myocardial infarction. N Engl J Med (1993) 2.14
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet (2001) 2.13
The Cellular Reaction to Silica. Can Med Assoc J (1935) 2.11
Tissue factor (thromboplastin): localization to plasma membranes by peroxidase-conjugated antibodies. Science (1972) 2.07
Low-dose aspirin and stroke. "It ain't necessarily so". Stroke (1992) 2.04
Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation (1990) 2.01
Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation (2001) 2.01
Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome. N Engl J Med (1985) 1.99
Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol (1987) 1.99
Purification and characterization of bovine tissue factor. J Biol Chem (1981) 1.99
Neonatal atria and ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways. Cell (1986) 1.98
Management of stable coronary artery disease. Am Fam Physician (1997) 1.97
Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation (1999) 1.94
Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation (1996) 1.94
Noninvasive In vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice. Circulation (1998) 1.94
Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest (1996) 1.92
AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol (1999) 1.92
Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology (2006) 1.89
Cardiovascular disease in women. Circulation (1993) 1.87
Tissue factor revisited. Prog Hemost Thromb (1982) 1.86
Giant cell versus lymphocytic myocarditis. A comparison of their clinical features and long-term outcomes. Circulation (1991) 1.85
Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med (1984) 1.85